Theresanne DeMartino1, Rawad El Ghoul2, Lu Wang3, James Bena3, Stanley L Hazen4, Russel Tracy5, Sanjay R Patel6, Dennis Auckley7, Reena Mehra4,8. 1. Edward Via College of Osteopathic Medicine, Blacksburg, Virginia. 2. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University Hospitals Case Medical Center, Cleveland, OH. 3. Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH. 4. Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH. 5. Departments of Biochemistry and Pathology, University of Vermont, Burlington, VT. 6. Department of Medicine, University of Pittsburgh, Pittsburgh, PA. 7. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, MetroHealth Medical Center, Cleveland, OH. 8. Sleep Center, Neurologic Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
Abstract
STUDY OBJECTIVES: Data have demonstrated adverse health effects of sleep deprivation. We postulate that oxidative stress and systemic inflammation biomarkers will be elevated in relation to short-term and long-term sleep duration reduction. METHODS: We analyzed data from the baseline examination of a randomized controlled trial involving participants with moderate to severe obstructive sleep apnea (OSA). Baseline polysomnography provided the total sleep time (PSG-TST, primary predictor); self-reported habitual sleep duration (SR-HSD) data was collected. Morning measures of oxidative stress and systemic inflammation included: myeloperoxidase (MPO, pmol/L), oxidized low-density lipoprotein (ox-LDL, U/L), F2-isoprostane (ng/mg), paraoxonase 1 (PON1, nmol·min(-1)·mL(-1)), and aryl esterase (μmol·min(-1)·mL(-1)). Linear models adjusted for age, sex, race, body mass index (BMI), cardiovascular disease (CVD), smoking, statin/anti-inflammatory medications, and apnea-hypopnea index were utilized (beta estimates and 95% confidence intervals). RESULTS:One hundred forty-seven participants comprised the final analytic sample; they were overall middle-aged (51.0 ± 11.7 y), obese (BMI = 37.3 ± 8.1 kg/m(2)), and 17% had CVD. Multivariable models demonstrated a significant inverse association of PSG-TST and MPO (β [95% CI] = -20.28 [-37.48, -3.08], P = 0.021), i.e., 20.3 pmol/L MPO reduction per hour increase PSG-TST. Alternatively, a significant inverse association with ox-LDL and SR-HSD was observed (β [95% CI] = 0.98 [0.96, 0.99], P = 0.027), i.e., 2% ox-LDL reduction per hour increase SR-HSD. CONCLUSIONS: Even after consideration of obesity and OSA severity, inverse significant findings were observed such that reduced PSG-TST was associated with elevated MPO levels and SR-HSD with ox-LDL, suggesting differential up-regulation of oxidative stress and pathways of inflammation in acute versus chronic sleep curtailment. CLINICAL TRIAL REGISTRATION: NIH clinical trials registry number NCT00607893.
RCT Entities:
STUDY OBJECTIVES: Data have demonstrated adverse health effects of sleep deprivation. We postulate that oxidative stress and systemic inflammation biomarkers will be elevated in relation to short-term and long-term sleep duration reduction. METHODS: We analyzed data from the baseline examination of a randomized controlled trial involving participants with moderate to severe obstructive sleep apnea (OSA). Baseline polysomnography provided the total sleep time (PSG-TST, primary predictor); self-reported habitual sleep duration (SR-HSD) data was collected. Morning measures of oxidative stress and systemic inflammation included: myeloperoxidase (MPO, pmol/L), oxidized low-density lipoprotein (ox-LDL, U/L), F2-isoprostane (ng/mg), paraoxonase 1 (PON1, nmol·min(-1)·mL(-1)), and aryl esterase (μmol·min(-1)·mL(-1)). Linear models adjusted for age, sex, race, body mass index (BMI), cardiovascular disease (CVD), smoking, statin/anti-inflammatory medications, and apnea-hypopnea index were utilized (beta estimates and 95% confidence intervals). RESULTS: One hundred forty-seven participants comprised the final analytic sample; they were overall middle-aged (51.0 ± 11.7 y), obese (BMI = 37.3 ± 8.1 kg/m(2)), and 17% had CVD. Multivariable models demonstrated a significant inverse association of PSG-TST and MPO (β [95% CI] = -20.28 [-37.48, -3.08], P = 0.021), i.e., 20.3 pmol/L MPO reduction per hour increase PSG-TST. Alternatively, a significant inverse association with ox-LDL and SR-HSD was observed (β [95% CI] = 0.98 [0.96, 0.99], P = 0.027), i.e., 2% ox-LDL reduction per hour increase SR-HSD. CONCLUSIONS: Even after consideration of obesity and OSA severity, inverse significant findings were observed such that reduced PSG-TST was associated with elevated MPO levels and SR-HSD with ox-LDL, suggesting differential up-regulation of oxidative stress and pathways of inflammation in acute versus chronic sleep curtailment. CLINICAL TRIAL REGISTRATION: NIH clinical trials registry number NCT00607893.
Authors: Nicole G Altman; Bilgay Izci-Balserak; Elizabeth Schopfer; Nicholas Jackson; Pinyo Rattanaumpawan; Philip R Gehrman; Nirav P Patel; Michael A Grandner Journal: Sleep Med Date: 2012-11-08 Impact factor: 3.492
Authors: Hans K Meier-Ewert; Paul M Ridker; Nader Rifai; Meredith M Regan; Nick J Price; David F Dinges; Janet M Mullington Journal: J Am Coll Cardiol Date: 2004-02-18 Impact factor: 24.094
Authors: Sanjay R Patel; Najib T Ayas; Mark R Malhotra; David P White; Eva S Schernhammer; Frank E Speizer; Meir J Stampfer; Frank B Hu Journal: Sleep Date: 2004-05-01 Impact factor: 5.849
Authors: Marius C Staiculescu; Christopher Foote; Gerald A Meininger; Luis A Martinez-Lemus Journal: Int J Mol Sci Date: 2014-12-19 Impact factor: 5.923
Authors: Bharati Prasad; Alana D Steffen; Hans P A Van Dongen; Francis M Pack; Inna Strakovsky; Bethany Staley; David F Dinges; Greg Maislin; Allan I Pack; Terri E Weaver Journal: Sleep Date: 2018-02-01 Impact factor: 5.849
Authors: Kelly A Stockelman; Anthony R Bain; Caitlin A Dow; Kyle J Diehl; Jared J Greiner; Brian L Stauffer; Christopher A DeSouza Journal: Am J Physiol Heart Circ Physiol Date: 2021-01-08 Impact factor: 4.733